Mezzasalma Advisors LLC Purchases 2,452 Shares of Sanofi (NASDAQ:SNY)

Mezzasalma Advisors LLC increased its position in shares of Sanofi (NASDAQ:SNY) by 24.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,686 shares of the company’s stock after buying an additional 2,452 shares during the period. Mezzasalma Advisors LLC’s holdings in Sanofi were worth $612,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of SNY. Northwest Investment Counselors LLC bought a new position in shares of Sanofi during the 3rd quarter worth approximately $29,000. Synergy Asset Management LLC bought a new position in Sanofi during the fourth quarter worth $25,000. Concord Wealth Partners grew its holdings in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the period. Sunbelt Securities Inc. grew its holdings in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the period. Finally, Fortitude Family Office LLC increased its stake in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $53.35 on Friday. The company has a market cap of $135.39 billion, a PE ratio of 21.43, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57. The company has a quick ratio of 0.74, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The business has a 50 day moving average price of $49.72 and a 200-day moving average price of $52.37.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. Equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on SNY. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.